Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Warrants And Rights Outstanding

Warrants And Rights Outstanding at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$308.19M+3,316%

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-75.9%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WarrantsAndRightsOutstanding.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s warrants and rights outstanding?
Citius Oncology, Inc. (CTOR) reported warrants and rights outstanding of $6.13M in Q3 2025.
What does warrants and rights outstanding mean?
This represents additional warrants or rights instruments that are classified outside of standard equity line items, often due to specific contractual terms or accounting classifications. It captures potential equity dilution that may not be reflected in primary share counts. Monitoring this helps investors account for all potential sources of future share issuance.